Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The use of asciminib versus ponatinib for multiresistant CML

Jorge Cortes • 29 Sep 2022
SOHO 2022
Chronic Myeloid Leukemia Leukemia Asciminib Ponatinib

Jorge Cortes, MD, Augusta University, Augusta, GA, comments on the use of asciminib versus ponatinib for patients with multiresistant chronic myeloid leukemia (CML), highlighting the value of both of these agents and important factors to consider when choosing between the two. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jorge Cortes

2:12
Key emerging trials in CML and the importance of improving treatment-free remission rates
Jorge Cortes • 7 Sep 2023
2:09
Social determinants of health & their impact on patients with hematological malignancies
Jorge Cortes • 7 Sep 2023
1:57
Post-hoc analysis of OPTIC: patient responses to ponatinib by T315I mutational status
Jorge Cortes • 7 Sep 2023
2:21
Exciting updates in the field of CML: disease pathophysiology & novel agents
Jorge Cortes • 7 Sep 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals